Psychedelics for alzheimer's disease-related dementia : Unveiling therapeutic possibilities and pathways
Copyright © 2024 Elsevier B.V. All rights reserved..
Psychedelics have traditionally been used for spiritual and recreational purposes, but recent developments in psychotherapy have highlighted their potential as therapeutic agents. These compounds, which act as potent 5-hydroxytryptamine (5HT) agonists, have been recognized for their ability to enhance neural plasticity through the activation of the serotoninergic and glutamatergic systems. However, the implications of these findings for the treatment of neurodegenerative disorders, particularly dementia, have not been fully explored. In recent years, studies have revealed the modulatory and beneficial effects of psychedelics in the context of dementia, specifically Alzheimer's disease (AD)-related dementia, which lacks a definitive cure. Psychedelics such as N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and Psilocybin have shown potential in mitigating the effects of this debilitating disease. These compounds not only target neurotransmitter imbalances but also act at the molecular level to modulate signalling pathways in AD, including the brain-derived neurotrophic factor signalling pathway and the subsequent activation of mammalian target of rapamycin and other autophagy regulators. Therefore, the controlled and dose-dependent administration of psychedelics represents a novel therapeutic intervention worth exploring and considering for the development of drugs for the treatment of AD-related dementia. In this article, we critically examined the literature that sheds light on the therapeutic possibilities and pathways of psychedelics for AD-related dementia. While this emerging field of research holds great promise, further studies are necessary to elucidate the long-term safety, efficacy, and optimal treatment protocols. Ultimately, the integration of psychedelics into the current treatment paradigm may provide a transformative approach for addressing the unmet needs of individuals living with AD-related dementia and their caregivers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Ageing research reviews - 96(2024) vom: 15. Apr., Seite 102211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sinha, Jitendra Kumar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arr.2024.102211 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367968061 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367968061 | ||
| 003 | DE-627 | ||
| 005 | 20240415233151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arr.2024.102211 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM367968061 | ||
| 035 | |a (NLM)38307424 | ||
| 035 | |a (PII)S1568-1637(24)00029-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sinha, Jitendra Kumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Psychedelics for alzheimer's disease-related dementia |b Unveiling therapeutic possibilities and pathways |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Psychedelics have traditionally been used for spiritual and recreational purposes, but recent developments in psychotherapy have highlighted their potential as therapeutic agents. These compounds, which act as potent 5-hydroxytryptamine (5HT) agonists, have been recognized for their ability to enhance neural plasticity through the activation of the serotoninergic and glutamatergic systems. However, the implications of these findings for the treatment of neurodegenerative disorders, particularly dementia, have not been fully explored. In recent years, studies have revealed the modulatory and beneficial effects of psychedelics in the context of dementia, specifically Alzheimer's disease (AD)-related dementia, which lacks a definitive cure. Psychedelics such as N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and Psilocybin have shown potential in mitigating the effects of this debilitating disease. These compounds not only target neurotransmitter imbalances but also act at the molecular level to modulate signalling pathways in AD, including the brain-derived neurotrophic factor signalling pathway and the subsequent activation of mammalian target of rapamycin and other autophagy regulators. Therefore, the controlled and dose-dependent administration of psychedelics represents a novel therapeutic intervention worth exploring and considering for the development of drugs for the treatment of AD-related dementia. In this article, we critically examined the literature that sheds light on the therapeutic possibilities and pathways of psychedelics for AD-related dementia. While this emerging field of research holds great promise, further studies are necessary to elucidate the long-term safety, efficacy, and optimal treatment protocols. Ultimately, the integration of psychedelics into the current treatment paradigm may provide a transformative approach for addressing the unmet needs of individuals living with AD-related dementia and their caregivers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 5-Hydroxytryptamine receptors | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a Brain-derived neurotrophic factor | |
| 650 | 4 | |a Dementia | |
| 650 | 4 | |a Psychedelics | |
| 650 | 4 | |a Tropomyosin receptor kinase B | |
| 650 | 7 | |a Hallucinogens |2 NLM | |
| 650 | 7 | |a Lysergic Acid Diethylamide |2 NLM | |
| 650 | 7 | |a 8NA5SWF92O |2 NLM | |
| 650 | 7 | |a Psilocybin |2 NLM | |
| 650 | 7 | |a 2RV7212BP0 |2 NLM | |
| 650 | 7 | |a N,N-Dimethyltryptamine |2 NLM | |
| 650 | 7 | |a WUB601BHAA |2 NLM | |
| 700 | 1 | |a Trisal, Anchal |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Shampa |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Krishna Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Sung Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Mahapatra, Madhumita |e verfasserin |4 aut | |
| 700 | 1 | |a Abomughaid, Mosleh Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Abomughayedh, Ali M |e verfasserin |4 aut | |
| 700 | 1 | |a Almutary, Abdulmajeed G |e verfasserin |4 aut | |
| 700 | 1 | |a Iqbal, Danish |e verfasserin |4 aut | |
| 700 | 1 | |a Bhaskar, Rakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Prabhu Chandra |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Saurabh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Niraj Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Abhishek Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ageing research reviews |d 2002 |g 96(2024) vom: 15. Apr., Seite 102211 |w (DE-627)NLM119138735 |x 1872-9649 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2024 |g day:15 |g month:04 |g pages:102211 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arr.2024.102211 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2024 |b 15 |c 04 |h 102211 | ||